within Pharmacolibrary.Drugs.ATC.A;

model A03CB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.08,
    Cl             = 64.4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.0017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Methylscopolamine in combination with psycholeptics is a formulation used primarily for the treatment of gastrointestinal disorders such as peptic ulcer, functional gastrointestinal disorders, and irritable bowel syndrome. Methylscopolamine is an antimuscarinic agent with peripheral anticholinergic effects. The drug combination is not commonly used nowadays, having been replaced by newer agents, and is not widely approved or marketed in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult healthy individuals as published reference PK studies for the combination of methylscopolamine and psycholeptics are lacking; estimates based on single-agent methylscopolamine pharmacokinetics after oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A03CB01;
